Answer
Tebentafusp has a terminal half-life of 6–8 hours in patients with metastatic uveal melanoma, decreasing to 10–14 minutes in the subset with anti-drug antibody titres above the median of 8192.
Sources for this answer
- KIMMTRAK (tebentafusp) 200 micrograms/ mL concentrate for solution for infusionImmunocore Limited · emc · SmPC §5.2 Pharmacokinetic properties · Version 2Document updated
Sources checked